SCHEMBL21560109

SCHEMBL21560109

O=C(Cc1csc(-c2ccc(Cl)cc2Cl)n1)N[C@H](C(=O)O)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SHMT1 P34896 14/20 0.72
SHMT2 P34897 12/20 0.71
EGLN1 Q9GZT9 2/20 0.56
PTGER1 P34995 1/20 0.46
PRKD3 O94806 1/20 0.46
PRKCG P05129 1/20 0.46
PRKCB P05771 1/20 0.46
IL1R1 P14778 1/20 0.46
PRKCA P17252 1/20 0.46
TNFRSF1A P19438 1/20 0.46
PRKCH P24723 1/20 0.46
PRKCI P41743 1/20 0.46
PRKCE Q02156 1/20 0.46
PRKCQ Q04759 1/20 0.46
PRKCZ Q05513 1/20 0.46
PRKCD Q05655 1/20 0.46
PRKD1 Q15139 1/20 0.46
TLR7 Q9NYK1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21560027 1.00 SHMT1 (0.72) SHMT1SHMT2EGLN1PTGER1PRKD3
SCHEMBL21560101 1.00 SHMT1 (0.72) SHMT1SHMT2EGLN1PTGER1PRKD3
SCHEMBL20255630 0.89 EGLN1 (0.57) SHMT1SHMT2EGLN1
SCHEMBL21560158 0.89 EGLN1 (0.57) SHMT1SHMT2EGLN1
SCHEMBL20255635 0.89 EGLN1 (0.57) SHMT1SHMT2EGLN1
SCHEMBL21560349 0.88 SHMT1 (0.59) SHMT1SHMT2EGLN1PTGER1
SCHEMBL20255684 0.87 SHMT1 (0.66) SHMT1SHMT2EGLN1
SCHEMBL20255548 0.86 EGLN1 (0.57) SHMT1SHMT2EGLN1TLR7
SCHEMBL20255544 0.86 EGLN1 (0.57) SHMT1SHMT2EGLN1TLR7
SCHEMBL20255638 0.86 EGLN1 (0.57) SHMT1SHMT2EGLN1TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11091451-B2 SHMT inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2021-08-17 US disclosed
US-20190345119-A1 SHMT INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2019-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091451-B2 SHMT inhibitors and uses thereof SHMT1, SHMT2, BHMT SHMT1 1/4885SHMT2 2/4885EGLN1 250/4885
US-20190345119-A1 SHMT INHIBITORS AND USES THEREOF SHMT1, SHMT2, BHMT SHMT1 1/4885SHMT2 2/4885EGLN1 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.